Cerenome, Inc. (CNSY) Income Statement
CNSY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCNSY revenue and net income
Where CNSY's revenue goes
2025Each bar shows an amount and its share of revenue. CNSY kept −429.4% of revenue as net income.
CNSY profit margins
CNSY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −10.5% | +185.5% | +76.7% | −3.7% |
| Gross profit | −4.1% | — | — | +0.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CNSY quarterly EPS vs estimates
Cerenome beat the analyst EPS estimate in 1 of the last 5 quarters. Next report: October 29, 2026 (estimate $-0.98).
CNSY income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $5.8M | $4.9M | $224,000 | $0 | $303,000 | $7.0M | $3.0M | $6.4M | $11.4M |
| Cost of revenue | $445,000 | $852,000 | $9.7M | $712,000 | $66,000 | $2.7M | $0 | $1.1M | $1.3M | $2.7M |
| Gross profit | $4.8M | $5.0M | −$4.8M | −$488,000 | −$66,000 | −$2.4M | $7.0M | $1.8M | $5.1M | $8.7M |
| Research & development | $8.4M | $10.6M | $9.7M | $9.7M | $5.3M | $3.5M | $5.4M | $5.5M | $13.4M | $16.2M |
| Sales, general & admin | $12.1M | $9.9M | $8.5M | $10.2M | $6.9M | $6.4M | $5.3M | $5.6M | $11.2M | $12.2M |
| Total operating expenses | $20.1M | $19.7M | $8.5M | $19.2M | $12.4M | $7.2M | $10.7M | $10.8M | $25.8M | $28.4M |
| Operating income | −$15.3M | −$14.7M | −$13.3M | −$19.7M | −$12.5M | −$9.6M | −$3.7M | −$8.8M | −$20.7M | −$19.7M |
| Interest income | $116,000 | $273,000 | $400,000 | $147,000 | — | — | — | — | — | — |
| Interest expense | $3.6M | $3.7M | $395,000 | $711,000 | $932,000 | $1.1M | $1.9M | $1.9M | $2.0M | $2.6M |
| Income before taxes | −$22.4M | −$13.0M | −$13.3M | −$20.3M | −$13.4M | −$8.2M | −$3.3M | −$8.9M | −$22.7M | −$22.0M |
| Net income | −$22.4M | −$13.0M | −$13.3M | −$20.3M | −$13.4M | −$8.2M | −$10.9M | −$12.6M | −$22.7M | −$22.0M |
| EBITDA | −$18.3M | −$8.4M | −$12.3M | −$18.9M | −$12.0M | −$8.4M | −$532,000 | −$6.6M | −$18.5M | −$18.3M |
| EPS (diluted) | −$32.06 | −$51.40 | −$112.55 | −$295.23 | −$422.06 | −$47030.53 | — | — | −$162138.04 | −$251605.26 |
| Gross margin | 91.5% | 85.4% | −97.2% | −217.9% | — | −791.1% | 100.0% | 61.5% | 79.4% | 76.1% |
| Operating margin | −293.5% | −252.3% | −271.1% | −8,800.0% | — | −3,163.0% | −52.3% | −293.7% | −322.6% | −173.2% |
| Net margin | −429.4% | −222.8% | −271.0% | −9,051.3% | — | −2,719.8% | −155.6% | −423.5% | −353.9% | −193.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $411,000 | $1.0M | $1.4M | $1.4M | $1.4M | $1.1M | $1.4M | $1.5M | $1.3M | $1.7M | $1.3M | $1.2M |
| Cost of revenue | $151,000 | $109,000 | $92,000 | $86,000 | $86,000 | $181,000 | $232,000 | $232,000 | $202,000 | $186,000 | $182,000 | $188,000 |
| Gross profit | $260,000 | $919,000 | $1.3M | $1.3M | $1.3M | $878,000 | $1.2M | $1.2M | $1.1M | $1.5M | $1.1M | $1.1M |
| Research & development | $4.3M | $2.9M | $2.9M | $2.4M | $1.2M | $1.8M | $2.2M | $2.9M | $2.8M | $2.8M | $2.8M | $2.5M |
| Sales, general & admin | $5.2M | $5.3M | $4.2M | $3.4M | $1.7M | $2.8M | $3.1M | $2.4M | $2.2M | $2.2M | $2.4M | — |
| Total operating expenses | $9.3M | $8.0M | $7.0M | $5.8M | $2.8M | $4.4M | $5.1M | $5.0M | $4.8M | $4.8M | $5.0M | $4.3M |
| Operating income | −$9.1M | −$7.1M | −$5.7M | −$4.5M | −$1.5M | −$3.5M | −$3.9M | −$3.8M | −$3.7M | −$3.3M | −$3.9M | −$3.3M |
| Interest income | $56,000 | $190,000 | $29,000 | $59,000 | $27,000 | $1,000 | — | — | — | — | — | — |
| Interest expense | $5,000 | $17,000 | $3.1M | $0 | $0 | $3.8M | $57,000 | $61,000 | $3.6M | $34,000 | $62,000 | $87,000 |
| Income before taxes | −$9.0M | −$6.9M | −$5.7M | −$4.4M | $5.2M | −$17.4M | −$3.9M | −$2.9M | −$2.9M | −$3.3M | −$3.8M | −$3.2M |
| Net income | −$9.0M | −$6.9M | −$5.7M | −$4.4M | $5.2M | −$17.4M | −$3.9M | −$2.9M | −$2.9M | −$3.3M | −$3.8M | −$3.2M |
| EBITDA | −$8.9M | −$6.8M | −$2.3M | −$4.3M | $5.3M | −$13.5M | −$3.6M | −$2.6M | $834,000 | −$3.0M | −$3.7M | −$2.9M |
| EPS (diluted) | −$1.31 | −$1.05 | −$1.03 | −$1.00 | −$0.16 | −$29.86 | −$16.55 | −$9.15 | −$6.84 | −$18.86 | −$21.06 | −$24.95 |
| Gross margin | 63.3% | 89.4% | 93.3% | 93.8% | 93.8% | 82.9% | 83.6% | 84.1% | 84.2% | 88.9% | 86.1% | 84.8% |
| Operating margin | −2,203.6% | −692.5% | −420.0% | −320.8% | −110.6% | −333.9% | −276.2% | −260.9% | −289.1% | −196.7% | −294.0% | −262.2% |
| Net margin | −2,191.2% | −675.7% | −417.9% | −316.6% | 370.6% | −1,643.2% | −276.4% | −197.4% | −229.9% | −194.5% | −290.2% | −259.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CNSY's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CNSY financial results
In fiscal year 2025 (ended December 31, 2025), Cerenome reported revenue of $5.2 million, down 10.5% from the year before. It had a net loss of $22.4 million, a net profit margin of −429.4%. Diluted earnings per share came to −$32.06. Over five years revenue grew at an average rate of 76.7% a year.
See the CNSY stock overview for the latest quote and news, or the CNSY chart for price history and technical indicators.
CNSY income statement FAQ
What is Cerenome's annual revenue?
Cerenome reported total revenue of $5.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 10.5% from $5.8 million the previous year.
Is Cerenome profitable?
No. Cerenome reported a net loss of $22.4 million in fiscal 2025, a net profit margin of −429.4%; its operating margin was −293.5%.
What is Cerenome's gross margin?
Cerenome's gross margin was 91.5% in fiscal 2025: for every $100 of revenue, Cerenome kept $91 after the direct cost of its products and services.
How much does Cerenome spend on research and development?
Cerenome spent $8.4 million on research and development in fiscal 2025, 160.7% of revenue.
How fast is Cerenome growing?
Revenue grew 76.7% a year on average over the last five fiscal years, from $0.3 million to $5.2 million.
What are Cerenome's earnings per share?
Cerenome earned $-32.06 per diluted share in fiscal 2025, compared with $-51.40 a year earlier.
When will Cerenome report its next earnings?
Cerenome is expected to report results for the quarter ending September 30, 2026 on October 29, 2026.
When does Cerenome's fiscal year end?
Cerenome's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.